APONTIS PHARMA AG (APPH.DE) Stock Fundamental Analysis
FRA:APPH - DE000A3CMGM5 - Common Stock
10.8 EUR
+0.1 (+0.93%)
APPH gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 50 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for APPH as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, APPH is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year APPH was profitable.
APPH had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: APPH reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: APPH reported negative operating cash flow in multiple years.
1.2 Ratios
With a Return On Assets value of 2.82%, APPH is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
APPH's Return On Equity of 4.03% is on the low side compared to the rest of the industry. APPH is outperformed by 60.00% of its industry peers.
The Return On Invested Capital of APPH (2.95%) is worse than 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.82% | ||
| ROE | 4.03% | ||
| ROIC | 2.95% |
ROA(3y)-4.49%
ROA(5y)-3.77%
ROE(3y)-9.48%
ROE(5y)-12.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
APPH's Profit Margin of 1.75% is on the low side compared to the rest of the industry. APPH is outperformed by 60.00% of its industry peers.
The Operating Margin of APPH (2.47%) is worse than 62.00% of its industry peers.
APPH's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 57.57%, APPH is doing worse than 66.00% of the companies in the same industry.
In the last couple of years the Gross Margin of APPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.47% | ||
| PM (TTM) | 1.75% | ||
| GM | 57.57% |
OM growth 3Y-32.75%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
2. Health
2.1 Basic Checks
APPH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
APPH has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, APPH has less shares outstanding
There is no outstanding debt for APPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 5.97 indicates that APPH is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.97, APPH belongs to the best of the industry, outperforming 86.00% of the companies in the same industry.
There is no outstanding debt for APPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.97 |
ROIC/WACC0.41
WACC7.13%
2.3 Liquidity
A Current Ratio of 4.44 indicates that APPH has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.44, APPH belongs to the top of the industry, outperforming 96.00% of the companies in the same industry.
APPH has a Quick Ratio of 3.37. This indicates that APPH is financially healthy and has no problem in meeting its short term obligations.
APPH has a Quick ratio of 3.37. This is amongst the best in the industry. APPH outperforms 92.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.44 | ||
| Quick Ratio | 3.37 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 106.67% over the past year.
APPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.12%.
Measured over the past years, APPH shows a small growth in Revenue. The Revenue has been growing by 3.89% on average per year.
EPS 1Y (TTM)106.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.67%
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%43.76%
3.2 Future
APPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 128.83% yearly.
APPH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.31% yearly.
EPS Next Y188.29%
EPS Next 2Y154.69%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue Next Year10.35%
Revenue Next 2Y16.83%
Revenue Next 3Y19.03%
Revenue Next 5Y15.31%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 72.00, which means the current valuation is very expensive for APPH.
Based on the Price/Earnings ratio, APPH is valued a bit more expensive than the industry average as 66.00% of the companies are valued more cheaply.
APPH's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.07.
Based on the Price/Forward Earnings ratio of 33.09, the valuation of APPH can be described as expensive.
Based on the Price/Forward Earnings ratio, APPH is valued a bit more expensive than the industry average as 66.00% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.59, APPH is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 72 | ||
| Fwd PE | 33.09 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, APPH is valued a bit more expensive than 62.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 19.05 |
4.3 Compensation for Growth
APPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as APPH's earnings are expected to grow with 128.83% in the coming years.
PEG (NY)0.38
PEG (5Y)N/A
EPS Next 2Y154.69%
EPS Next 3Y128.83%
5. Dividend
5.1 Amount
No dividends for APPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:APPH (9/9/2025, 7:00:00 PM)
10.8
+0.1 (+0.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners40.82%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap91.80M
Analysts37.78
Price Target10.2 (-5.56%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-25.93%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-26.27%
EPS NY rev (3m)-26.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 72 | ||
| Fwd PE | 33.09 | ||
| P/S | 1.28 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.96 | ||
| P/tB | 6.87 | ||
| EV/EBITDA | 19.05 |
EPS(TTM)0.15
EY1.39%
EPS(NY)0.33
Fwd EY3.02%
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS8.43
BVpS3.65
TBVpS1.57
PEG (NY)0.38
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.82% | ||
| ROE | 4.03% | ||
| ROCE | 4.51% | ||
| ROIC | 2.95% | ||
| ROICexc | 4.86% | ||
| ROICexgc | 18.85% | ||
| OM | 2.47% | ||
| PM (TTM) | 1.75% | ||
| GM | 57.57% | ||
| FCFM | N/A |
ROA(3y)-4.49%
ROA(5y)-3.77%
ROE(3y)-9.48%
ROE(5y)-12.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-34.78%
ROICexcg growth 5YN/A
ROICexc growth 3Y-37.05%
ROICexc growth 5YN/A
OM growth 3Y-32.75%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
F-Score5
Asset Turnover1.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 104.52% | ||
| Cap/Sales | 3.27% | ||
| Interest Coverage | 13.13 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.44 | ||
| Quick Ratio | 3.37 | ||
| Altman-Z | 5.97 |
F-Score5
WACC7.13%
ROIC/WACC0.41
Cap/Depr(3y)153.41%
Cap/Depr(5y)119.86%
Cap/Sales(3y)6.51%
Cap/Sales(5y)4.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)106.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.67%
EPS Next Y188.29%
EPS Next 2Y154.69%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%43.76%
Revenue Next Year10.35%
Revenue Next 2Y16.83%
Revenue Next 3Y19.03%
Revenue Next 5Y15.31%
EBIT growth 1Y113.23%
EBIT growth 3Y-33.96%
EBIT growth 5YN/A
EBIT Next Year419.89%
EBIT Next 3Y131.3%
EBIT Next 5YN/A
FCF growth 1Y66.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.97%
OCF growth 3YN/A
OCF growth 5YN/A